To date, several potentially curative lentiviral vector (LVV) based cell and gene therapies have been approved by the US FDA, and many more are in clinical trials. LVV play a crucial role in delivering transgenes into immune cells to correct genetic defects.
LVV design involves selecting a suitable backbone, promoter, and enhancer sequences to drive gene expression in the targeted cells. To successfully package such vectors, transgene of interest, regulatory elements and packaging signal are all essential components.
The LVV manufacturing process involves multiple steps including plasmid construction, transfection of packaging cells, vector production, purification, and quality control. During this process, many challenges (e.g., scalability, purification, quality control, GMP compliance, genetic stability) need to be carefully addressed to unlock the full potential of LVV-based cell and gene therapies. As advancements continue, overcoming these challenges will pave the way for broader clinical applications and improved patient outcomes.
This Roundtable discussion will draw together several acknowledged experts from the fields of LVV design, manufacture, and regulation to examine the key current trends in the space, and point the way to future success.